These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9224380)

  • 1. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
    Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
    J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
    Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
    Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
    Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
    Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
    Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
    Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors.
    Albers P; Ulbright TM; Albers J; Miller GA; Orazi A; Crabtree WN; Baniel J; Reister T; Sidner RA; Foster RS; Donohue JP
    J Urol; 1996 Feb; 155(2):579-86. PubMed ID: 8558664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New parameters for prediction of pathological stage in clinical stage I non-seminomatous testicular tumors].
    Albers P; Ulbright TM; Albers J; Miller GA; Foster RS; Donohue JP
    Urologe A; 1995 Jul; 34(4):316-23. PubMed ID: 7676541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
    Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
    Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
    Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
    J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
    Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
    J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
    Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
    Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
    Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
    J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
    Fernandez EB; Sesterhenn IA; McCarthy WF; Mostofi FK; Moul JW
    J Urol; 1994 Oct; 152(4):1133-8. PubMed ID: 7915335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease.
    Olivarez D; Ulbright T; DeRiese W; Foster R; Reister T; Einhorn L; Sledge G
    Cancer Res; 1994 May; 54(10):2800-2. PubMed ID: 7513256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer.
    Moul JW; Snow PB; Fernandez EB; Maher PD; Sesterhenn IA
    J Urol; 1995 May; 153(5):1674-7. PubMed ID: 7715008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection.
    Hermans BP; Sweeney CJ; Foster RS; Einhorn LE; Donohue JP
    J Urol; 2000 Jun; 163(6):1721-4. PubMed ID: 10799168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
    Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
    J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
    Fukuda S; Shirahama T; Imazono Y; Tsushima T; Ohmori H; Kayajima T; Take S; Nishiyama K; Yonezawa S; Akiba S; Akiyama S; Ohi Y
    Cancer; 1999 Mar; 85(6):1323-30. PubMed ID: 10189138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
    Divrik RT; Akdoğan B; Ozen H; Zorlu F
    J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
    Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
    J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination.
    Franchi A; Gallo O; Boddi V; Santucci M
    Clin Cancer Res; 1996 Oct; 2(10):1801-8. PubMed ID: 9816133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.